JP2017533946A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533946A5
JP2017533946A5 JP2017526527A JP2017526527A JP2017533946A5 JP 2017533946 A5 JP2017533946 A5 JP 2017533946A5 JP 2017526527 A JP2017526527 A JP 2017526527A JP 2017526527 A JP2017526527 A JP 2017526527A JP 2017533946 A5 JP2017533946 A5 JP 2017533946A5
Authority
JP
Japan
Prior art keywords
methyl
amino
carboxamide
pyrazine
oxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017526527A
Other languages
English (en)
Japanese (ja)
Other versions
JP6779204B2 (ja
JP2017533946A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/060509 external-priority patent/WO2016081290A1/en
Publication of JP2017533946A publication Critical patent/JP2017533946A/ja
Publication of JP2017533946A5 publication Critical patent/JP2017533946A5/ja
Application granted granted Critical
Publication of JP6779204B2 publication Critical patent/JP6779204B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017526527A 2014-11-18 2015-11-13 A2a拮抗薬特性を有するアミノピラジン化合物 Expired - Fee Related JP6779204B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081262P 2014-11-18 2014-11-18
US62/081,262 2014-11-18
PCT/US2015/060509 WO2016081290A1 (en) 2014-11-18 2015-11-13 Aminopyrazine compounds with a2a antagonist properties

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020138418A Division JP2020193211A (ja) 2014-11-18 2020-08-19 A2a拮抗薬特性を有するアミノピラジン化合物

Publications (3)

Publication Number Publication Date
JP2017533946A JP2017533946A (ja) 2017-11-16
JP2017533946A5 true JP2017533946A5 (enExample) 2018-12-20
JP6779204B2 JP6779204B2 (ja) 2020-11-04

Family

ID=56014406

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017526527A Expired - Fee Related JP6779204B2 (ja) 2014-11-18 2015-11-13 A2a拮抗薬特性を有するアミノピラジン化合物
JP2020138418A Withdrawn JP2020193211A (ja) 2014-11-18 2020-08-19 A2a拮抗薬特性を有するアミノピラジン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020138418A Withdrawn JP2020193211A (ja) 2014-11-18 2020-08-19 A2a拮抗薬特性を有するアミノピラジン化合物

Country Status (11)

Country Link
US (1) US10472347B2 (enExample)
EP (1) EP3220910B1 (enExample)
JP (2) JP6779204B2 (enExample)
KR (1) KR20170083136A (enExample)
CN (1) CN107106558A (enExample)
AU (1) AU2015350315B2 (enExample)
BR (1) BR112017010261A2 (enExample)
CA (1) CA2967944C (enExample)
MX (1) MX381180B (enExample)
RU (1) RU2727805C2 (enExample)
WO (1) WO2016081290A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102598895B1 (ko) * 2016-07-12 2023-11-07 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ,インコーポレイテッド アロステリックshp2阻害剤としての二環式化合物
CN108570054B (zh) * 2017-03-07 2021-07-16 广州再极医药科技有限公司 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用
MX2020000693A (es) 2017-07-18 2020-07-29 Nuvation Bio Inc Compuestos de 1,8-naftiridinona, y usos de los mismos.
AU2018302179A1 (en) 2017-07-18 2020-02-13 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
AU2018325451A1 (en) 2017-08-31 2020-03-05 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor
MX2020003579A (es) 2017-10-12 2020-07-22 Revolution Medicines Inc Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos.
EP3723754A4 (en) 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. IMIDAZO [1,2-C] QUINAZOLINE-5-AMINE COMPOUNDS WITH PROPERTIES OF A2A ANTAGONIST
TW201927791A (zh) 2017-12-15 2019-07-16 美商銳新醫藥公司 作為變構shp2抑制劑的多環化合物
WO2020037094A1 (en) 2018-08-16 2020-02-20 Innate Tumor Immunity, Inc. Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
US20200079793A1 (en) * 2018-08-31 2020-03-12 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating adenosine a2b receptor and adenosine a2a receptor
EP3883576B1 (en) 2018-11-20 2025-12-17 Merck Sharp & Dohme LLC Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
KR20210093964A (ko) 2018-11-20 2021-07-28 머크 샤프 앤드 돔 코포레이션 치환된 아미노 트리아졸로피리미딘 및 아미노 트리아졸로피라진 아데노신 수용체 길항제, 제약 조성물 및 그의 용도
KR102653800B1 (ko) 2018-11-30 2024-04-01 머크 샤프 앤드 돔 엘엘씨 아데노신 수용체 길항제로서의 9-치환된 아미노 트리아졸로 퀴나졸린 유도체, 제약 조성물 및 그의 용도
CA3120331A1 (en) 2018-11-30 2020-06-04 Merck Sharp & Dohme Corp. 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
JOP20210164A1 (ar) 2019-01-11 2023-01-30 Omeros Corp طرق وتركيبات علاج السرطان
AU2020208644A1 (en) 2019-01-18 2021-08-26 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
WO2020150676A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
TW202128650A (zh) * 2019-10-11 2021-08-01 德商拜耳動物保健有限公司 作為殺蟲劑之新穎的雜芳基取代之吡𠯤衍生物
CN111285798A (zh) * 2020-04-09 2020-06-16 阿里生物新材料(常州)有限公司 一种(3-环丙基吡啶-2-基)甲胺盐酸盐的合成方法
CN111423364A (zh) * 2020-05-19 2020-07-17 阿里生物新材料(常州)有限公司 一种(3-环丙基吡啶-2-基)甲胺的合成方法
EP3929189A1 (en) * 2020-06-25 2021-12-29 Bayer Animal Health GmbH Novel heteroaryl-substituted pyrazine derivatives as pesticides
MX2023011269A (es) 2021-03-23 2024-01-17 Bioage Labs Inc Inhibidores del inflamasoma nlrp3.
CN119053602A (zh) 2022-01-28 2024-11-29 柏奥艾奇实验室公司 Nlrp3炎性体的n-氧化物抑制剂
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
US12516018B2 (en) * 2023-03-30 2026-01-06 Brandeis University Solid-solid phase change aromatic azo compounds, method of manufacture, and use for thermal energy storage and release
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US12509459B2 (en) 2024-03-26 2025-12-30 BioAge Labs, Inc. Inhibitors of NLRP3 inflammasome

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
ES2165393T3 (es) 1993-07-27 2002-03-16 Kyowa Hakko Kogyo Kk Remedio contra la enfermedad de parkinson.
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
MY132006A (en) 2000-05-26 2007-09-28 Schering Corp ADENOSINE A2a RECEPTOR ANTAGONISTS
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
AU2004247615B2 (en) * 2003-06-18 2008-02-21 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as CB1 modulators
EP1678160A1 (en) * 2003-10-27 2006-07-12 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
US20060199828A1 (en) * 2005-03-04 2006-09-07 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
ES2270715B1 (es) * 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
WO2010141275A1 (en) 2009-06-01 2010-12-09 Merck Sharp & Dohme Corp. Pyrazine carboxamide orexin receptor antagonists

Similar Documents

Publication Publication Date Title
JP2017533946A5 (enExample)
RU2017120853A (ru) Аминопиразиновые соединения со свойствами антагониста a2a
KR101819433B1 (ko) 인돌린-2-온 또는 피롤로-피리딘-2-온 유도체
JP4672820B2 (ja) GABAα5リガンドとしての置換1,2,4−トリアゾロ[3,4−a]フタラジン誘導体
US9321756B2 (en) Azole compounds as PIM inhibitors
MX2011012345A (es) Inhibidores de pi3k/mtor basados en benzoxazepinas contra enfermedades proliferativas.
CN111556871B (zh) 作为PDE1抑制剂的1H-吡唑并[4,3-b]吡啶
JP2016500073A5 (enExample)
JP2014528446A5 (enExample)
JP2013527173A5 (enExample)
JP2013508404A5 (enExample)
JP2017530960A5 (enExample)
RU2007101544A (ru) Антагонисты рецепторов высвобождающего гонадотропин гормона
JP2013508403A5 (enExample)
ME02437B (me) Disupstituirani oktahidropirolo[3,4-c]piroli kao modulatori oreksin receptora
WO2010126895A1 (en) Inhibitors of pi3 kinase and / or mtor
ME02802B (me) P2x7 modulatori
AU2011338389A1 (en) Bicyclic compounds as Pim inhibitors
JP2013508405A5 (enExample)
CN120826403A (zh) Shp2抑制剂化合物及其应用
RU2015114936A (ru) Ингибиторы серин/треонинкиназы
KR101898364B1 (ko) 인돌린-2-온 및 1,3-다이하이드로-피롤로[3,2-c]피리딘-2-온 유도체
KR20150047609A (ko) 피리딘 유도체 및 의약
CN114502537A (zh) 突变型idh2抑制剂及其应用
RU2015125306A (ru) Новые соединения ингибиторы фосфодиэстеразы типа 10а